Söndag 24 November | 00:15:25 Europe / Stockholm
Svenska | English

2cureX

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-27 15:00 Bokslutskommuniké 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 - Årsstämma
2024-02-29 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-11-14 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-29 - Kvartalsrapport 2023-Q1
2023-05-26 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 - Årsstämma
2023-02-23 - Bokslutskommuniké 2022
2023-02-10 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 - Årsstämma
2021-05-27 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-07-02 - Extra Bolagsstämma 2020
2020-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 - Årsstämma
2020-05-28 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 - Årsstämma
2019-05-17 - Kvartalsrapport 2019-Q1
2019-04-02 - Extra Bolagsstämma 2019
2019-03-01 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-29 - X-dag ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 - Årsstämma
2018-05-18 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamt inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Störst verksamhet innehas på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)
2023-07-05 08:30:00

2cureX will be holding its Q2 2023 online presentation with a Q&A session on July 12, 2023 at 20.00 (CET).

2cureX Management will present status on the published goals for 2023 and additional important achievements.

From 2023, 2cureX has been arranging a Q&A session (hosted by Stokk.io) shortly after the end of each quarter (Q2 on July 12) and a video commentary (hosted by Infront Direkt) on the same day we publish the quarterly report (Q2 report on August 24). The new Q&A format allows you to submit questions both today or during the live event. You can sign up via the following link: Q&A webcast for Q2 2023). Stokk.io will act as moderator during the Q&A session.

The event will be livestreamed on the same link. The event is recorded and transcribed and made available for all investors afterwards on our website. 

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com
 
Certified Adviser: Redeye AB

Attachments

Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden